Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Mortality in Hypertrophic Cardiomyopathy.

Aglan, Amro; Fath, Ayman R; Eldaly, Abdullah S; Anderson, Allen S; Phillips, Jason S; Maron, Barry J; Maron, Martin S; Rowin, Ethan J

Aglan, Amro; Fath, Ayman R; Eldaly, Abdullah S; Anderson, Allen S; Phillips, Jason S; Maron, Barry J; Maron, Martin S; Rowin, Ethan J.

Afiliación

Aglan A; Hypertrophic Cardiomyopathy Center, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
Fath AR; University of Texas Health Science Center at San Antonio, Texas, USA.
Eldaly AS; Houston Methodist Hospital, Houston, Texas, USA.
Anderson AS; University of Texas Health Science Center at San Antonio, Texas, USA.
Phillips JS; University of Texas Health Science Center at San Antonio, Texas, USA.
Maron BJ; Hypertrophic Cardiomyopathy Center, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
Maron MS; Hypertrophic Cardiomyopathy Center, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
Rowin EJ; Hypertrophic Cardiomyopathy Center, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.

JACC Adv ; 3(3): 100843, 2024 Mar.

Article en En | MEDLINE | ID: mdl-38938829

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JACC Adv Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google